How much does Biopharma Process Systems Limited make?

Biopharma Process Systems Limited reported revenue of £10.1m and £142k profit in the year to 31 Dec 2024, according to its accounts filed at Companies House.

How many employees does Biopharma Process Systems Limited have?

Biopharma Process Systems Limited reported an average of 66 employees in the year to 31 Dec 2024.

Is Biopharma Process Systems Limited profitable?

Yes — Biopharma Process Systems Limited reported a profit of £142k in the year to 31 Dec 2024.

Company No. 02337313 · Incorporated 23 Jan 1989

Biopharma Process Systems Limited

Registered name: BIOPHARMA PROCESS SYSTEMS LIMITED

Part of Pe487 Limited group

Biopharma Process Systems Limited made £10.1m revenue and £142k profit in the year to 31 Dec 2024. read from filing text

Biopharma Process Systems Limited’s revenue fell 29% to £10.1m in the year to 31 Dec 2024, with £142k profit and 66 employees. The company is classified under “research and experimental development on biotechnology” and is based in Winchester; we hold 3 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology SIC 74909Other professional, scientific and technical activities n.e.c.

Status: Active
Location: Winchester, South East
Age: 37 yrs · since 1989
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The parent company of Biopharma Process Systems Limited is PE487 Limited and its registered office is Biopharma House, Winnall Valley Road, Winchester, Hampshire, SO23 0LD.”

Latest accounts · year to 31 Dec 2024

Key figures

Cash flow filed

Revenue

£10.1m

Growth ▼28.7%

Profit

£142k

Growth ▼87.2%

Profit margin

1.4%

Gross 21.9%

Employees

Change ▲10%

Profit / employee

£2.1k

Revenue/employee £153k

Profitable streak

3yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2022	31 Dec 2023	31 Dec 2024
Disclosure	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text
Profit & loss
Revenue (turnover)	£14m	£14.2m	£10.1m
Cost of sales	£9.3m	£11m	£7.9m
Gross profit	£4.7m	£3.2m	£2.2m
Operating profit	£2.7m	£1.4m	£46k
Profit before tax	£2.7m	£1.4m	£154k
Profit after tax	£2.3m	£1.1m	£142k
Profit (best available)	£2.3m	£1.1m	£142k
Staff costs	£3.2m	£3.2m	£3.6m
Employees (average)	69	60	66
Ratios
Profit margin	16.5%	7.8%	1.4%
Gross margin	33.8%	22.4%	21.9%
Revenue per employee	£202k	£236k	£153k
Profit per employee	£33.3k	£18.4k	£2.1k
Cash conversion	−100.8%	−108.9%	371%
Growth (year on year)
Revenue growth	—	▲1.3%	▼28.7%
Profit growth	—	▼51.9%	▼87.2%
Headcount growth	—	▼13%	▲10%
Balance sheet — indirect signals, not revenue
Cash at bank	£5.8m	£5.1m	£4.2m
Net assets	£9m	£9.2m	£9.4m
Fixed assets	£1.9m	£2.9m	£3.4m
Current assets	£11.2m	£9.2m	£10.4m
Debtors	£3.2m	£2.2m	£2.4m
Deferred income	£860k	£650k	£1.2m
Cash from operations	−£2.7m	−£1.5m	£171k
Source	FullAccounts · bulk data Aug 2024	FullAccounts · bulk data Aug 2024	FullAccounts · bulk data Jul 2025

Derived from the latest filing

How the business works

Profit margin: 1.4%; Profit ÷ revenue.
Gross margin: 21.9%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £153k; Revenue ÷ average employees.
Profit per employee: £2.1k; Profit ÷ average employees.
Cash conversion: 371%; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 33.6%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 11.7%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 24%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲2%; Now £9.4m
Cash at bank: ▼17%; Now £4.2m
Headcount: ▲10%; Now 66
Deferred income: ▲81%; Now £1.2m
Fixed assets: ▲16%; Now £3.4m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Pe487 Limitedultimate parent75–100%
Biopharma Process Systems Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Subsidiaries (1)

Biopharma Overseas LimitedFigures not disclosed

Sister companies (3)

Biopharma Technology LimitedFigures not disclosed
Easytesters LimitedRev. — · Profit £65.2k
Pe489 LimitedRev. — · Profit −£76.5k

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2024 (profit £142k), from the Companies House accounts bulk data published Jul 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.